Kathy Lang

Senior Vice President, Head of Evidence, Value, and Access

Kathy brings more than 30 years of experience in health economics & outcomes research, and market access to her role as Senior Vice President, Head of Evidence, Value, and Access at Cytel. An accomplished industry executive and strategic advisor, she has a proven track record of building and leading high-performing global teams, growing businesses, and helping pharmaceutical and biotechnology companies develop evidence strategies that demonstrate product value and support successful market access.

Prior to joining Cytel, Kathy served as Principal of Evidence to Access, an independent strategic consulting practice, and as Executive Vice President and Partner at PrecisionAQ, where she held executive leadership responsibility for a multidisciplinary HEOR and market access strategy business, bringing together specialized teams, expanding client partnerships, and driving business growth and operational performance.

Throughout her career, she has partnered with pharmaceutical and biotechnology leaders to shape evidence generation and value strategies, prioritize investments in evidence development, and translate complex scientific and economic evidence into compelling value propositions for payers, regulators, clinicians, and other stakeholders. Her experience spans the pharmaceutical industry and consulting sector, with expertise across the product lifecycle, from early development through commercialization.

An active contributor to industry thought leadership, Kathy has authored dozens of peer-reviewed publications and participated in scientific conferences addressing emerging challenges and opportunities in HEOR and market access, including real-world evidence, integrated evidence planning, artificial intelligence, and evolving health technology assessment requirements.

Kathy holds a Bachelor of Science in Economics from Suffolk University and a PhD in Economics from Boston College.